ALSO NOTED: Diabetes-med use doubles in young girls; Ranbaxy settles patent fight with Astellas;

> Tween and teen girls drove a huge increase in type 2 diabetes prescriptions among kids. Report

> India's Ranbaxy Laboratories has resolved a patent fight over the prostate drug Tamsulosin, a generic version of Astellas Pharma's Flomox, allowing it to launch the product in March 2010. Report

> Barr Pharmaceuticals fell short of analysts' estimates on third-quarter earnings and may do so again in the fourth quarter, the company announced today. Report

> King Pharmaceutical beat third-quarter earnings estimates with profits of $128 million on revenues of $544.9 million. Report

> Drug distributor Amerisource Bergen boosted its stock buyback program by $500 million. Report

> Cytos Biotechnology has won a round of kudos for its experimental vaccine to control hypertension. The therapy controls blood pressure with an occasional jab, as opposed to a regimen of daily pills. Report

> By all accounts, New Jersey's referendum to back embryonic stem cell research with $450 million in borrowed funds was supposed to be something of a cakewalk. Instead, proponents like Governor Jon Corzine were body slammed with a resounding 53 percent of the electorate coming out against the ESC proposal. Report

> Sanofi-Aventis has launched a mid-stage study of a new seasonal flu vaccine that hopes to advance a completely new method to make vaccines. Report

And Finally... Forget Avandia and go hungry instead. Fasting slows diabetes and prevents heart disease, a new study shows. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.